RIGOL Technologies Co., Ltd. (RIGOL) received strong shareholder backing across all agenda items at its 2026 First Extraordinary General Meeting (EGM) held on 13 October 2026 in Suzhou, Jiangsu Province.
Attendance and voting base • Issued share capital at the meeting date totalled 218.68 million shares, of which 310,557 A-shares were held in treasury and carried no voting rights. • Shares eligible to vote therefore stood at 218.37 million. Holders and proxies representing 124.41 million shares—56.98% of the valid voting base—were present. • No shareholders were required to abstain, and none indicated opposition in advance.
Key resolutions approved Ordinary resolutions 1. Re-appointment of the Company’s auditor for 2026: 99.97% votes in favour (124.38 million shares). 2. Shareholder Dividend Distribution Plan for 2026-2028: 99.98% votes in favour (124.39 million shares).
Special resolutions 3. Adoption of the 2026 Restricted Share Incentive Scheme (Draft) and summary: 99.80% votes in favour (124.17 million shares). 4. Appraisal and Management Measures for the incentive scheme: 99.97% votes in favour (124.38 million shares). 5. Authorisation for the Board to manage equity incentive matters: 99.97% votes in favour (124.38 million shares). 6. Change of registered capital and corresponding amendments to the Articles of Association: 99.97% votes in favour (124.38 million shares).
Governance and compliance Jun He Law Offices supervised the meeting, while Tricor Investor Services Limited acted as scrutineer. The company confirmed that convening, voting and procedural requirements complied with the PRC Company Law, the Hong Kong Listing Rules and RIGOL’s Articles of Association.
Articles of Association updated The shareholder-approved amendments to the Articles of Association take immediate effect. The revised document is available on both the HKExnews website and RIGOL’s corporate site.
Board attendance Executive Directors Dr. Wang Yue, Mr. Wang Ning, Dr. Sun Ningxiao and Mr. Cheng Jianchuan, alongside Independent Non-executive Directors Dr. Qin Ce, Dr. Liu Liansheng and Ms. Xu Xu, participated in person or via teleconference.